Trial Profile
Phase I Study of TK216 in Patients With Relapsed and Refractory Leukemias
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 08 May 2019
Price :
$35
*
At a glance
- Drugs ONCT 216 (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 02 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Nov 2018 Status changed from planning to not yet recruiting.
- 07 Sep 2017 New trial record